Renal clear cell carcinoma (KIRC), an immunogenic tumor type in which immunotherapies such as IL-2 [25], IFN-α [26], and nivolumab [27] have shown clinical benefit in a subset of patients, had the second-highest median TIS scores but fairly low mutation load. Here, IFNA1 is linked to neoplasm.